The structural features that govern broad-spectrum activity of broadly neutralizing anti-ebolavirus antibodies (Abs) outside of the internal fusion loop epitope are currently unknown. Here we describe the structure of a broadly neutralizing human monoclonal Ab (mAb), ADI-15946, which was identified in a human survivor of the 2013-2016 outbreak. The crystal structure of ADI-15946 in complex with cleaved Ebola virus glycoprotein (EBOV GP CL ) reveals that binding of the mAb structurally mimics the conserved interaction between the EBOV GP core and its glycan cap β17-β18 loop to inhibit infection. Both endosomal proteolysis of EBOV GP and binding of mAb FVM09 displace this loop, thereby increasing exposure of ADI-15946's conserved epitope and enhancing neutralization. Our work also mapped the paratope of ADI-15946, thereby explaining reduced activity against Sudan virus, which enabled rational, structure-guided engineering to enhance binding and neutralization of Sudan virus while retaining the parental activity against EBOV and Bundibugyo virus.
BOV and related members of the family Filoviridae cause outbreaks of highly lethal disease in humans. Ab therapeutics such as ZMapp 1 , mAb114 2 and a three-mAb cocktail from Regeneron Pharmaceuticals (REGN-EB3) 3 have recently been proposed for emergency use against Ebola virus disease 4 . However, the activity of these therapies is limited to EBOV and does not extend protection to the related virulent ebolaviruses Bundibugyo virus (BDBV) and Sudan virus (SUDV). Both BDBV and SUDV have caused sizeable outbreaks in the past and their potential for re-emergence remains unknown. No therapeutics are currently available for the treatment of BDBV and SUDV, which lends urgency to discovery and characterization of broadly active mAbs. The key obstacle for generation of such mAbs stems from limited amino acid sequence conservation among the glycoproteins of ebolaviruses, with only 50% amino acid identity shared between EBOV and SUDV, the two most prevalent ebolaviruses. Detailed characterization of known broadly neutralizing antibodies (bNAbs) and their modes of action will be critical to the design of next-generation broadly protective Ab cocktails and vaccines that elicit broadly protective responses.
All Ab therapeutics currently under development for Ebola virus disease target the ebolavirus surface glycoprotein, GP, which mediates viral entry into host cells by catalyzing viral membrane fusion in host cell endosomes 1, 2, 5 . During biogenesis, GP is posttranslationally processed to yield GP1 and GP2 subunits ( Fig. 1a) , held together by a single disulfide bond, which associate into a trimer of GP1,2 heterodimers 6, 7 . GP1 mediates host cell attachment and receptor recognition, whereas GP2 mediates fusion of the viral and host membranes [8] [9] [10] [11] [12] . The GP2 amino acid sequence, which includes the internal fusion loop (IFL), is highly conserved among ebolaviruses 6 while the glycan cap and mucin-like domains of GP1 show higher sequence diversity. During infection, EBOV GP undergoes host-programmed disassembly mediated by endosomal cysteine proteases (cathepsins B and L), which shed the steric bulk of the extensively glycosylated glycan cap and mucin-like domains and generate the cleaved GP intermediate (GP CL ) 13, 14 . This in turn unmasks the receptor-binding site in GP1 and reveals other previously inaccessible regions of the GP core 12, 15, 16 . Engagement of the intracellular entry receptor Niemann-Pick C1 (NPC1) by the viral receptor-binding site is proposed to induce conformational rearrangements in GP CL that culminate in viral membrane fusion 12, [16] [17] [18] [19] . Antibodies targeting the functionally critical and conserved viral fusion machinery offer an efficacious mode of viral entry inhibition and have been shown to be strongly protective [20] [21] [22] [23] [24] .
The only pan-ebolavirus neutralizing Abs reported thus far target overlapping epitopes in the viral IFL 21, [23] [24] [25] [26] . In contrast, lowresolution negative stain reconstructions of the recently isolated human survivor mAb, ADI-15946, suggest that it may recognize a distinct footprint in the base region of GP, crosslinking the GP1 and GP2 subunits 20 . ADI-15946 potently neutralizes EBOV and BDBV but lacks neutralizing and protective activity against SUDV 20 . Accordingly, we sought to define the structural determinants of ADI-15946 activity in the context of its cognate antigen, EBOV GP, to characterize features of both its epitope and paratope that confer broad reactivity while investigating its limited activity against SUDV.
Results
Crystal structure of EBOV GP CL -ADI-15946 complex. We determined the crystal structure of ADI-15946's fragment antigen binding (Fab) in complex with EBOV GP CL to 4.1 Å resolution (Fig. 1a,b and Table 1) 20 . The structure was solved by molecular replacement using the previously published EBOV GP CL structure as a search model (PDB 5HJ3) and was refined to an R work / R free of 26.2 / 28.1% (Table 1) 16 . The ADI-15946 Fab targets the base of a single GP1/GP2 protomer in the GP trimer at an approximately 45° angle relative to the surface of GP, with its constant domains directed downward toward the viral membrane (Fig. 1b) .
The heavy and light chains each contribute roughly half of the overall ADI-15946 binding interface: ~55% from the heavy chain complementarity-determining region 3 (CDR H3), and the remaining 45% from the combined contributions of the light chain framework region 3 (FRL3) and CDRs 1, 2 and 3 (L1, L2 and L3, respectively) ( Fig. 1b,c) . Notably, CDRs 1 and 2 of the heavy chain (H1 and H2, respectively) do not participate in the Fab-GP CL interface (Fig. 1b,c) . Instead, heavy chain recognition of GP CL is mediated exclusively by the CDR H3 that is 22 amino acids long, which buries roughly 465 Å 2 of surface area on binding (Fig. 1b ). The footprint of ADI-15946 partially overlaps those of the EBOVmonospecific binders KZ52, c2G4 and c4G7 (Supplementary Note 1) 6, 27 . However, ADI-15946 probably gains cross-reactivity from an upward shift of its footprint that allows it to target a highly conserved pocket above the upper boundary of the KZ52 epitope as suggested previously (Fig. 1d) 20 .
Modeling ADI-15946 interactions with GP2 and the glycan cap. ADI-15946 heavy chain contacts include the strictly conserved lysine at position 510 in the GP2 N terminus-where a substitution to glutamic acid, K510E, was previously shown to give rise to escape from BDBV viral neutralization 20 . We have confirmed that the same amino acid substitution in EBOV GP also leads to the loss of binding and neutralization phenotypes (data not shown). The electrostatic surface of ADI-15946 is complementary to that of GP, and our sidechain modeling suggests that the K510E substitution introduces a charged/steric clash with residues D100 C and/or L100 F of CDR H3 thereby explaining the loss of antiviral activity ( Fig. 2a -c). We tested ADI-15946 variants containing alanine substitutions at either the D100 C or the L100 F positions for binding and neutralization and observed loss of both activities against recombinant vesicular stomatitis virus (rVSV) particles bearing BDBV GP K510E ( Fig. 2d ). Additionally, the ADI-15946 D100 C A variant lost activity to wild-type rVSV-BDBV GP probably due to the loss of stabilizing interactions between the D100 C sidechain and the backbone of CDR H3 (Fig. 2d ). These results indicated that interaction with the conserved K510 residue is a key contributor to ADI-15946's breadth and that overcoming the K510E escape mutation would be difficult without extensive mutagenesis of the antibody paratope.
Wec et al. 20 have shown that ADI-15946 inhibits GP proteolysis in vitro, a key step in unmasking of the viral receptor-binding site that is indispensable for infection. The left boundary of ADI-15946's footprint, formed by light chain FRL3, is in immediate proximity to the β13-β14 loop that passes over the IFL and is cleaved by endosomal cathepsins during viral entry ( Supplementary Fig. 1 Overlay of our structure with uncleaved GP (PDB 5JQ3) shows that ADI-15946 binding probably impedes protease access to this loop, thus explaining ADI-15946 inhibition of GP proteolysis ( Supplementary Fig. 1 ) 20 .
Competition with, and mimicry of, the β17-β18 loop. ADI-15946 binds into a hydrophobic pocket formed by residues 71-75 of GP1, which fold into a 3 10 helix, and is hereafter termed the '3 10 pocket' (Fig. 3a,b ). The 3 10 helix rearranges in GP CL when bound to NPC1, and stabilization of this region by ADI-15946 CDR H3 may be part of the mAb's neutralization mechanism ( Fig. 3a ) 12, 16, 20 .
In uncleaved GP, the 3 10 pocket is occupied by the β17-β18 loop (GP1 residues 287-291) that extends down from the glycan cap ( Fig. 3a,b ) 12, 28 . Interactions of ADI-15946 CDR H3 residues D100 C , W100 D and L100 E with the 3 10 pocket mimic the contacts made by β17-β18 loop residues E292, W291, and F290, respectively ( Fig. 3b ). Correspondingly, we postulated that the viral β17-β18 loop peptide competes for binding with CDR H3 of ADI-15946 in full-length GP (GP FL ) ( Supplementary Fig. 2 ). To test the effect of β17-β18 loop removal on ADI-15946 binding and neutralization, we measured the apparent binding constant (K d app ) for ADI-15946 interaction with EBOV GP FL and GP CL via biolayer interferometry, as well as its neutralization of rVSV-EBOV GP FL and rVSV-EBOV GP CL . Consistent with the previous report, we observed a 10,000-fold improvement in binding and a 100-fold improvement in neutralization potency against EBOV GP CL compared to full-length GP ( Fig. 3e and Supplementary Tables 1 and 2) 20 . Comparison of association (k on ) and dissociation (k off ) rates of ADI-15946 to EBOV GP FL and GP CL showed that the improved binding to GP CL is primarily driven by an over 1,000-fold slower k off and a modest improvement of the association rate (10-fold increased k on ) ( Fig. 3f , Supplementary Fig. 3 and Supplementary Table 2 ). Given the sizeable contribution of CDR H3 to the binding interface, the slower dissociation rate against GP CL probably results from its unobstructed access to the 3 10 pocket.
To specifically probe the importance of the β17-β18 loop's hydrophobic packing into the 3 10 pocket to the shielding of the ADI-15946 epitope, we first tested ADI-15946 binding and neutralization against rVSVs bearing an EBOV GP variant with an arginine substitution at position 291 (rVSV-EBOV GP W291R ). Modeling of the arginine sidechain suggested that the W291R substitution would displace the β17-β18 loop from the conserved pocket by introducing charged and steric clashes with the GP2 residue asparagine 512. Consistent with this hypothesis, we observed a 10-fold enhancement in ADI-15946 binding and neutralization of rVSV-EBOV GP W291R compared to rVSV bearing wild-type EBOV GP (GP WT ) ( Fig. 3d ,e and Supplementary Table 1 ). We then tested ADI-15946 neutralization against rVSVs bearing an EBOV GPΔβ17-β18 variant in which the β17-β18 loop has been deleted (residues 187-198). Removal of the β17-β18 loop had no apparent adverse effects on viral infectivity or replication in vitro (data not shown). We observed a 10-fold increase in neutralization efficiency of rVSV-EBOV GPΔβ17-β18 compared to GP WT (Fig. 3c ). The intermediate neutralization potency of rVSV-EBOV GP W291R compared to GP CL and GP WT suggests that displacement of the β17-β18 loop from the 3 10 pocket is the limiting factor for binding of ADI-15946 to EBOV GP ( Fig. 3e ).
Enhancement of binding and neutralization with mAb FVM09.
Previous work suggests that a non-neutralizing mAb, FVM09, recognizes and 'peels away' the β17-β18 loop from the base, thereby enhancing neutralization by the base-binding mAb c2G4 29, 30 . Given the more profound role of the β17-β18 loop in restricting access of ADI-15946 to its base epitope (see above), we evaluated the hypothesis that FVM09 could also work together with ADI-15946 to neutralize virus with enhanced potency ( Supplementary Fig. 2 ). We first tested competition between ADI-15946 and FVM09 using biolayer interferometry-based competitive binding assays and found that both mAbs could bind to EBOV GP simultaneously ( Supplementary  Fig. 4 ). We next tested the effect of FVM09 on ADI-15946 neutralization of rVSV-EBOV GP or authentic EBOV in the presence of three fixed concentrations of FVM09. FVM09 potentiated ADI-15946 neutralization in a concentration-dependent manner by >10-fold, but had no effect on neutralization by KZ52 ( Fig. 4a ). Conversely, titration of FVM09 into a constant, subneutralizing concentration of ADI-15946 also showed dose-dependent enhancement of ADI-15946 neutralizing activity (Fig. 4b) . In contrast, KZ52 neutralization was reduced in the same assay, perhaps because KZ52 binds along the surface of the β17-β18 loop whereas ADI-15946 binds beneath the β17-β18 loop ( Fig. 4b and Supplementary Fig. 5 ). We observed similar neutralization enhancement trends with authentic EBOV (Fig. 4c,d ), and to a lesser extent, with rVSV-SUDV GP (Fig. 4e,f) . The functional importance of the strict conservation of the amino acid sequence in the 3 10 pocket and the β17-β18 loop among ebolavirus GPs remains unknown, but it may relate to the transduction of conformational changes in GP on NPC1 binding ( Fig. 3a and Supplementary Note 2) 12 . Our results demonstrate that rare neutralizing antibodies such as ADI-15946 can access and exploit this cryptic site of broad ebolavirus vulnerability to achieve neutralization, presumably by interfering with the region's functional role in viral entry. The enhancement of ADI-15946 binding and neutralization in the presence of β17-β18 loop binders such as FVM09 may reflect a mechanism by which specific combinations of glycan cap-and base-binding mAbs can synergize to interdict viral infection during a natural polyclonal immune response (Fig. 4g ). 
Molecular determinants for somatic maturation of ADI-15946.
To delineate the molecular basis of ADI-15946's broad activity, we assigned its light and heavy chain variable domain sequences to their most probable inferred germline progenitors (IGL) ( Fig. 5a and Supplementary Note 3). We found that reversion of three residues introduced by somatic hypermutation (SHM) in the variable heavy chain domain to germline (light chain, LC; heavy chain, HC) (LC WT :HC IGL ; CDR H3 is retained fully mature) had no appreciable impact on binding of full-length or cleaved EBOV, BDBV or SUDV GP or neutralization of rVSVs bearing EBOV, BDBV or SUDV GP (Fig. 5b,c and Supplementary Fig. 6 ). These findings agree with our structural observations, since only CDR H3 participates in binding to EBOV GP CL (Fig. 1b ). Reversion of 10 SHM-introduced residues in the variable heavy chain domain outside of CDR L3 (LC IGL :HC WT ; residues 3, 4, 27, 28, 31, 53, 67, 72, 87, 104) had a profound impact on neutralization of rVSVs bearing EBOV, BDBV or SUDV GP (Fig. 5b,c and Supplementary Fig. 6 ). Both the LC IGL :HC WT and the combined LC IGL :HC IGL Ab variants were non-neutralizing against rVSV-EBOV GP FL despite retaining a fully mature CDR H3 and CDR L3, suggesting that LC contacts outside of CDR L3 make key contributions to GP recognition (Fig. 5c ). The LC IGL :HC WT and the LC IGL :HC IGL germline-approximating Ab variants retained some neutralizing activity against EBOV GP CL and BDBV GP CL, probably due to improved access of CDR H3 to the 3 10 pocket ( Fig. 5c and Supplementary Table 1 ). However, LC IGL :HC IGL did not neutralize rVSV-SUDV GP CL ( Supplementary Fig. 6 ). Our germline-approximating variants LC IGL :HC WT and the LC IGL :HC IGL neutralized the rVSV-EBOV GP W291R variant more potently than rVSV-EBOV GP CL , which suggests that additional LC contacts that are absent in GP CL , probably between the Ab and the glycan cap, contribute to ADI-15946's activity against GP FL ( Supplementary Figs. 1 and 6 and Supplementary Table 1 ). T, temperature (310 ºK). e c , charge of an electron (1.60217646 × 10 -19 C). d, Binding and neutralization assays showing the capacity of ADI-15946 variants containing either the D100 C A or the L100 F A mutation to bind to rVSV-BDBV GP (wild type, WT or K510E) in an ELISA (top, mean ± s.d., n = 4 biologically independent samples) and neutralize infection by these viruses (bottom, mean ± s.d., n = 6 biologically independent samples). Electrostatic surface potentials in a and c were generated using the APBS plugin with Pymol. A 450 nm, absorbance at 450 nm.
Enhancement of ADI
its footprint ( Fig. 6f and Supplementary Note 2). There are only five nonconserved residues across all five ebolavirus GPs involved in the interface with ADI-15946, all located in GP2: N506, N514, H516, L547 and H549. These are predominantly contacted by CDR L2 and FRL3 (Fig. 6f ). However, CDR H3 contacts one key residue in EBOV GP (Asn 506) that is not conserved in SUDV GP (Arg 506).
Using this information, we separately mutated nearby residues in ADI-15946 CDR H3, R100 and Y100 A to alanine to reduce steric and charge clashes with SUDV R506. The ADI-15946 mutant Y100 A A showed decreased binding to both SUDV and BDBV GP compared to wild-type ADI-15946 ( Supplementary Fig. 7) . However, the mAb variant containing R100A, called 46M1, showed increased binding to SUDV GP ectodomain by ELISA and slightly improved neutralization of authentic virus compared to the parental antibody ( Fig. 6b-e and Supplementary Fig. 7 ). Structural alignment of additional Fab-GP complexes enabled comparison of the binding features of the ADI-15946 paratope with those of EBOV-monospecific mAbs KZ52, c2G4 and c4G7, which have overlapping epitopes with that of ADI-15946 ( Supplementary  Fig. 5 and Supplementary Note 1) 6, 27 . We observed that the heavy chain paratope of c4G7 places a tyrosine residue in a similar position and orientation to that of the ADI-15946 LC residue F67 and another tyrosine residue proximal to ADI-15946 LC residue S65. We then attempted to mimic this double tyrosine motif by incorporation of light chain S65Y and F67Y mutations into ADI-15946. The construct bearing heavy chain R100A and light chain S65Y is called variant 46M2, and ADI-15946 bearing the R100A/S65Y pair plus LC substitution F67Y is called variant 46M3 (Fig. 6a) . The 46M2 and 46M3 antibodies showed enhanced binding of SUDV, while maintaining parental binding to EBOV and BDBV GPs (Fig. 6b) .
The 46M2 and 46M3 antibodies also exhibited a 16-to 33-fold improvement in their capacity to neutralize SUDV GP-bearing rVSV and authentic SUDV respectively, while retaining neutralization of EBOV and BDBV (Fig. 6c-e and Supplementary Fig. 7) . Slight variations were observed in the neutralization profiles of the affinity variants versus the parent ADI-15946: we observed a roughly two-fold increase in neutralization for the affinity variants against rVSV-EBOV GP compared to wild-type ADI-15946 and a two-fold decrease in neutralization for the affinity variants against authentic EBOV compared to wild-type ADI-15946 (Fig. 6d,e and Supplementary Tables 1 and 3) . Further, the variants and the parental antibody similarly recognize the conserved 3 10 pocket, as all are equally enhanced by β17-β18 loop deletion and, such as the wildtype ADI-15946, 46M3 neutralization is enhanced in the presence of FVM09 ( Fig. 6g and Supplementary Fig. 8 ). We show that relatively few mutations introduced in the 46M2 and 46M3 variants resulted in improved binding and neutralization of SUDV and confirmed the importance of the LC FR3 region to the binding interface. 
Discussion
The crystal structure of ADI-15946 Fab in complex with EBOV GP CL and accompanying biochemistry and virology presented here illuminated antigenic features of GP that dictate access to a broadly conserved but previously unappreciated epitope shared by ebolaviruses. This site of vulnerability is shielded by the descending β17-β18 loop of the glycan cap, removal of which potentiates ADI-15946 activity. Our findings support a mechanism of action whereby ADI-15946 gains enhanced neutralizing activity against the endosomal, cleaved viral GP species generated by host proteases during entry. This feature allows ADI-15946 to neutralize both the extracellular and intracellular viral species. In contrast, other potent neutralizers that target the GP base, such as KZ52 and the ZMapp components c2G4 and c4G7, have been shown to lose their activity against GP CL and therefore have activity only against the extracellular virus 6, 20, 27 . The unique mechanism of neutralization by ADI-15946 may involve binding of ADI-15946 in the 3 10 pocket, which in turn prevents rearrangement of GP1 residues 71-75 on binding of GP CL to NPC1 by mimicking the hydrophobic interactions of the β17-β18 loop that packs into the pocket in GP FL (Fig. 3a,b) 12 . In addition, ADI-15946 may also inhibit conformational changes required for membrane fusion by anchoring to the GP1-GP2 interface across the IFL thereby preventing its unraveling from the GP1 core during fusion triggering.
We also uncovered potentially synergistic neutralization between ADI-15946 and FVM09, a non-neutralizing glycan cap-binding antibody. FVM09 was previously shown to enhance binding activity of another glycan cap mAb, m8C4, yet reduce binding of the basetargeting mAb KZ52-the latter being consistent with our own observations 30 . As with ADI-15946, mutations of the β17-β18 loop also enhanced m8C4's binding and neutralizing activity in vitro 30 . The exact mechanism of FVM09 and m8C4 cooperation is difficult to discern without structural details of the binding interface between the two mAbs and GP. In the case of cooperativity between FVM09 and ADI-15946, however, we propose that FVM09 primarily plays a supporting role by exposing the 3 10 pocket thereby enhancing ADI-15946 binding and neutralization. It is possible that co-administration of FVM09 and ADI-15946 would lead to enhancement in protective efficacy in vivo. However, given that FVM09 is a nonneutralizing and non-protective antibody, viral escape from ADI-15946 neutralization would render the two antibody combination non-protective. Follow up studies will be required to fully evaluate the therapeutic usefulness of such antibody combinations.
Our analysis of the contributions of somatic hypermutation to the binding and neutralization properties of ADI-15946 indicated that only a limited number of amino acid substitutions in the germline antibody sequence were required for binding of this conserved GP site and that many of these mutations occurred in the framework region. Klein et al. show that somatic mutations in the immunoglobulin framework region of antibodies against HIV-1 enhance affinity by decreasing the dissociation rate and are generally necessary to achieve broad neutralization 31 . We found that, similar to bNAbs against HIV-1, ADI-15946 also required somatic maturation of the framework region, which bestowed the mAb with an improved dissociation rate and broad neutralizing activity of ebolaviruses 31 . Specifically, as a result of SHM, a serine at position 67 of ADI-15946 FRL3 was replaced with an aromatic phenylalanine sidechain that interacts with GP2 residue H516 (100% conserved between EBOV, BDBV and SUDV). Interestingly, the non-pathogenic RESTV encodes a tyrosine at position 516 in GP2, which may play a role in the inability of ADI-15946 to neutralize RESTV due to steric hindrance with the antibody phenylalanine 67 ( Supplementary Fig. 7e and Supplementary Note 2).
This structure provided the molecular details of the paratope required for rational engineering of the parent mAb to expand its activity against SUDV. We showed that structure-guided substitutions, two in the FRL3 and one in CDR H3, enhanced both binding and neutralization activity against SUDV without loss of activity against EBOV or BDBV. However, follow-up work will be required to evaluate additional mAb variants and their biophysical properties to ensure favorable in vivo pharmacokinetics and protective efficacy against SUDV since, unlike natural antibodies, mAbs generated through in vitro engineering have not undergone immune tolerance selection. Our work also details structural features of GP recognition by a broadly active anti-ebolavirus antibody and suggests specific strategies such as the use of GP CL (lacking the glycan cap) or GP variants with β17-β18 loop deletion to enable targeting higher value is tighter binding) for binding of ADI-15946 variants (WT, IGL and WT:IGL chimeras) to GP CL to their capacity to neutralize rVSV-EBOV GP infection (1/IC 50 ; higher value is more potent neutralization). c, Heat maps for neutralization of rVSVs bearing ebolavirus GP and GP CL proteins by the indicated ADI-15946 variants. of the highly conserved site in the design of vaccines and immunotherapeutics. Like ADI-15946, the pan-ebolavirus mAb ADI-15878 also binds into a cryptic pocket at a distinct site in the GP base, that is typically occupied by the N-terminal tail of GP2 when not bound by the mAb 21 . Future ebolavirus vaccine designs may strive to enhance the exposure of both of these vulnerable pockets on a single antigen by developing an immunogen that combines β17-β18 loop deletion with a truncated GP2 N terminus. Such immunogens may help elicit bNAbs such as ADI-15946 at a higher frequency while minimizing potential for viral escape by eliciting bNAbs towards multiple broadly conserved sites, both located proximal to the functionally critical region of the GP fusion loop. A broadly reactive vaccine would afford increased preparedness against ebolavirus disease regardless of the specific virus responsible for an outbreak.
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